Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20 Years: A Bibliometric Analysis Via CiteSpace and VOSviewer
L Miao, J Shi, H Yu, L Song, C Zhu, D Shi… - Journal of the American …, 2023 - Am Heart Assoc
The conjunction of atrial fibrillation (AF) and venous thromboembolism (VTE) is common in
clinical practice. Over the last 2 decades, a significant number of articles (2500) have been …
clinical practice. Over the last 2 decades, a significant number of articles (2500) have been …
Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity
BL Erstad, JF Barletta - Annals of Pharmacotherapy, 2023 - journals.sagepub.com
Objective: The objective of the study was to discuss the controversies surrounding the use
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …
Efficacy and safety of factor Xa inhibitors in low body weight patients
Y Tan, C Hubbard, H Owens, J Pitt… - … : The Journal of …, 2024 - Wiley Online Library
Abstract Study Objective The purpose of this study is to provide evidence for the safety and
efficacy of factor Xa inhibitors in patients with a weight≤ 60 kg or BMI< 18.5 kg/m2. Design …
efficacy of factor Xa inhibitors in patients with a weight≤ 60 kg or BMI< 18.5 kg/m2. Design …
[HTML][HTML] The Safety and Effectiveness of Apixaban in Patients with End-Stage Kidney Disease Dialysis: A Retrospective Observational Study
W El Nekidy, E Abidi, S Nabil, S Kendakji, M Ali… - Journal of Clinical …, 2024 - mdpi.com
Background: Apixaban has been increasingly utilized for various FDA-approved indications,
including stroke prevention and venous thromboembolism (VTE) treatment in patients with …
including stroke prevention and venous thromboembolism (VTE) treatment in patients with …
Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial
Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …
DOAC compared with warfarin for VTE in low weight patients: A retrospective cohort study conducted through the VENUS network
KA Martin, N Lancki, LB Kreuziger, C Li… - Thrombosis …, 2023 - thrombosisresearch.com
1. Background Direct oral anticoagulants (DOACs), including apixaban, dabigatran,
edoxaban, and rivaroxaban, are approved for the treatment and prevention of venous …
edoxaban, and rivaroxaban, are approved for the treatment and prevention of venous …
[HTML][HTML] Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study
Background and aims. Edoxaban proved to be safe and effective also in fragile patients, but
its administration thorough percutaneous endoscopic gastrostomy (PEG) has not been …
its administration thorough percutaneous endoscopic gastrostomy (PEG) has not been …
[HTML][HTML] Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
Background Little is published about warfarin therapy adherence patterns beyond 6 months
of initial anticoagulant treatment and their association with effectiveness and safety for …
of initial anticoagulant treatment and their association with effectiveness and safety for …
[HTML][HTML] Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …